Trial DesignRationale and design of the fractional flow reserve versus angiography for multivessel evaluation (FAME) study
Section snippets
Study design
The objective of the FAME study is to compare the clinical outcomes and cost-effectiveness of an FFR-guided PCI strategy to an angiography-guided one in patients with multivessel CAD. FAME is a multicenter, international, prospective, randomized trial including men and women aged ≥18 years in whom multivessel PCI is planned. Eligible patients must have lesions that are ≥50% narrowed and that the investigator feels require stenting in ≥2 major epicardial vessels. The vessels must be large enough
References (28)
- et al.
Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease
J Am Coll Cardiol
(2003) - et al.
Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity
Am J Cardiol
(2002) - et al.
Usefulness of fractional flow reserve for risk stratification of patients with multivessel coronary artery disease and an intermediate stenosis
Am J Cardiol
(2002) - et al.
Use of fractional myocardial flow reserve to assess the functional significance of intermediate coronary stenoses
Am J Cardiol
(2000) - et al.
Percutaneous coronary intervention of functionally non-significant stenosis: 5-year follow-up of the DEFER study
J Am Coll Cardiol
(2007) - et al.
Long-term clinical outcome after fractional flow reserve–guided percutaneous coronary intervention in patients with multivessel disease
J Am Coll Cardiol
(2005) - et al.
Thirty-month outcome after fractional flow reserve–guided versus conventional multivessel percutaneous coronary intervention
Am J Cardiol
(2005) - et al.
Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry
J Am Coll Cardiol
(2006) - et al.
Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials
J Am Coll Cardiol
(2006) - et al.
Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET)
Lancet
(2005)
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents
J Am Coll Cardiol
Is it time to measure fractional flow reserve in all patients?
J Am Coll Cardiol
The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase
Am Heart J
Long-term clinical outcome after fractional flow reserve–guided percutaneous coronary intervention in patients with multivessel disease
J Am Coll Cardiol
Cited by (75)
Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS
2018, Journal of the American College of CardiologyCitation Excerpt :The present study is a patient-level, post hoc, pooled analysis of the FFR-guided revascularization/deferral cohorts from 3 randomized controlled trials (Figure 1) (12–14). The detailed study protocols for each study have been published previously (15–17). In brief, FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) is a prospective, randomized, controlled, multicenter trial investigating the superiority of FFR-guided PCI over angiography-guided PCI in patients presenting with stable angina, unstable angina, or non–ST-segment elevation myocardial infarction (NSTEMI) (NCT00267774) (12,15).
Application of pressure-derived myocardial fractional flow reserve in chronic hemodialysis patients
2018, Journal of CardiologyCan Functional Testing for Ischemia and Viability Guide Revascularization?
2017, JACC: Cardiovascular ImagingThe Prognostic Value of Residual Coronary Stenoses after Functionally Complete Revascularization
2016, Journal of the American College of CardiologyCopeptin and high-sensitivity cardiac troponin to exclude severe coronary stenosis in patients with chest pain and coronary artery disease
2016, American Journal of Emergency Medicine